Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
VERAXA Biotech initiates a collaboration with Ardigen SA to optimize cancer target pair selection for growing BiTAC® pipeline.
-
VERAXA Biotech AG today announced the appointment of Carl von Halem as as Interim Chief Financial Officer.
-
VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”) today provided a company and pipeline update.
-
VERAXA Biotech announces further progress with lead BiTAC® T-cell engager (BiTAC-TCE) program, initiates cell line development with ATUM.
-
VERAXA Biotech has moved into additional laboratory space at its R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement.
-
VERAXA Biotech AG (NASDAQ: VRXA) has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform.